The inauguration ceremony for the Fosun Pharma Middle East Office and Fosunhenlius Middle East United Company was recently held in Jeddah, Saudi Arabia. This move marks a significant step in China-based Fosun Pharma’s localised operations in the Middle East, representing a strategic initiative by the company to continuously expand its global presence through innovation.
Currently, Fosun Pharma has established mature commercial networks in overseas markets such as the United States, Europe, Africa, India, and Southeast Asia, boasting an overseas commercial team of approximately 1,000 people.
In the Middle East, Fosun Pharma is steadily advancing deep cooperation with local partners and the registration process for innovative drugs: In April 2025, Fosun Pharma entered a strategic cooperation with Saudi Arabia’s Fakeeh Care Group to jointly promote the introduction of innovative products and therapies; In August 2025, Fosun Pharma’s self-developed innovative drug Luvometinib Tablets received Breakthrough Therapy Designation from the Saudi Food and Drug Authority, which will accelerate its clinical registration and commercialisation process in Saudi Arabia.
Fosunhenlius Middle East United Company is a strategic joint venture between SVax, a pioneering Saudi biopharmaceutical company, and Henlius, a global innovative biopharmaceutical enterprise under Fosun Pharma. Headquartered in Saudi Arabia, the company integrates world-class biologics R&D and manufacturing capabilities with deep local expertise in registration, commercialization, and healthcare access. For almost a decade, SVax has been at the forefront of Saudi Arabia’s efforts to localize vaccine and biologics manufacturing in line with Vision 2030 and the Saudi National Biotechnology Strategy.
